AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time...
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on...
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -5.8282208589 | 3.26 | 3.42 | 2.955 | 3357378 | 3.22450108 | CS |
4 | 0.09 | 3.02013422819 | 2.98 | 3.68 | 2.755 | 3950105 | 3.18952502 | CS |
12 | 0.32 | 11.6363636364 | 2.75 | 3.68 | 2.57 | 3063743 | 3.03499443 | CS |
26 | 0.32 | 11.6363636364 | 2.75 | 3.68 | 2.335 | 2517123 | 2.86887153 | CS |
52 | -2.11 | -40.7335907336 | 5.18 | 5.46 | 2.335 | 2011455 | 3.2443433 | CS |
156 | -6.23 | -66.9892473118 | 9.3 | 14.97 | 2.335 | 2021793 | 6.62241479 | CS |
260 | -57.93 | -94.9672131148 | 61 | 71.91 | 2.335 | 1946692 | 10.43883063 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales